Seprafilm Adhesion Barrier
seprafilm® Adhesion Barrier is indicated for the reduction of post-surgical adhesions1 associated with cardiac thoracic (e.g. valve surgery2), abdominal (e.g. Colectomy3) or pelvic laparotomy (e.g. myomectomy4 or C Section5). Adhesions related to these post-surgical procedures might resulted in infertility, chronic pelvic pain & small bowel obstruction. Seprafilm Adhesion Barrier is made up of 2 polysaccharides: sodium hyaluronate and carboxymethylcellulose. Seprafilm has obtained approval from the US FDA in 1996 and received the EMA Mark in 2011.
Reference: 1. Seprafilm Adhesion Barrier [package insert]. Cambridge, MA: Genzyme Biosurgery; 2008. | 2. Walther T et al. A novel adhesion barrier facilitates reoperations in complex congenital cardiac surgery. The Journal of Thoracic and Cardiovascular Surgery. J Thorac Cardiovasc Surg. 2005;129:359-63. | 3. Becker JM et al. Prevention of postoperative abdominal adhesions by a sodium hyaluronate-based bioresorbable membrane: a prospective, randomized, double-blind multicenter study. J Am Coll Surg. 1996;183:297-306. | 4. Diamond MP. Reduction of adhesions after uterine myomectomy by Seprafilm membrane (HAL-F): a blinded, prospective, randomized, multicenter clinical study. Seprafilm Adhesion Study Group. Fertil Steril. 1996;66:904-10. | 5. Fushiki H et al. Usefulness of Seprafilm During A Cesarean Section. Ob-Gyn Surgery. 2002;13:99-105.
Synvisc and Synvisc-One (Hylan G-F 20)
SYNVISC-ONE® (Hylan G-F 20) is viscosupplement used to treat pain associated with osteoarthritis in knee; and SYNVISC® is additionally indicated for treating pain associated with osteoarthritis in hip, ankle and shoulder; the most common application is osteoarthritis of knee joint. Synvisc and Synvisc-One have obtained approved from US FDA and European CE Mark. A course of Synvisc requires three injections and Synvisc-One is a next-generation viscosupplement which only requires one injection.
Reference: Synvisc/Synvisc One IFU March 2011